Alnylam Pharmaceuticals, Inc.

Ladies and gentlemen, thank you for standing by. Welcome to the Al Nilem Pharmaceuticals Conference Call, second quarter 2020. There will be a question and answer session to follow. Please be advised that this call is being taped at the company's request. I would now like to turn the call over to the company. Please go ahead.

Good morning. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Al Nilem. With me today on the phone are John Merriganori, Chief Executive Officer, Barry Green, President, Pasha Deschanel, President of R&D, Jeff Poulton, Chief Financial Officer, and Yvonne Greenstreet, Chief Operating Officer. Andy Orris, Head of the U.S. Business, is also on the phone and available for Q&A. For those of you participating via conference call, the accompanying slides can be accessed by going to the Events section of the Investors page of our website, investors.lnylam.com slash events. During today's call, as outlined in slide two, Jeff will provide some introductory remarks in general context. Daria will provide an update on our commercial and medical affairs progress. Akshay will review recent clinical and preclinical updates. Jeff will review our financials. And Yvonne will provide a brief summary of upcoming milestones before opening the call for your questions. I would like to remind you that this call will contain remarks concerning LNN's future expectations, plans, and prospects. which constitute forward-looking statements for the purpose of the safe harbor provision under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in our most recent quarterly report on file with the SEC. In addition, any forward-looking statements represent our view only as to the date of this recording. It should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update such statements. With that, I'd like to turn the call over to John.

Thanks, Christine, and thank you, everyone, for joining the call today. Let me start by expressing El Milo's support for Black Lives Matter and our support for the efforts to end systemic racism in our country. At El Milo, we stand against all forms of discrimination, and in our core, we believe in justice, equity, and inclusion. We stand in support of peaceful protests aimed at achieving real and sustainable change. Enough is enough and it's time to finally cure the refractory scourge of hate. I'd also like to comment briefly on the Trump administration's recent announcement on drug prices. While we fully support the need to reduce or even eliminate patient out-of-pocket costs for prescription drugs, The administration's proposal to potentially introduce a so-called most favored nation executive order is both unfortunate and misguided. Importing foreign price controls will harm American innovation and hurt our patients. Even if this executive order is finalized, we don't believe it will stand. With that, let's now turn to our business. As all of you know, the COVID-19 pandemic remains dynamic, uncertain, and unpredictable. and a new normal starting in Q4. While the pandemic continues or even worsens in many states in the U.S., we believe our Lyle's business is benefiting from our broad global presence. In spite of the ebbs and flows, we are seeing healthcare systems now remaining open, and we don't currently expect a repeat shutdown of healthcare systems like what was seen in Q2, especially in the April-May timeframe. Our confidence in the second half is reflected in an upward revision in our OnPatro revenue guidance range. Overall, we're really proud of our field teams around the world and their ability to adapt quickly and safely to meet the needs of patients, embodying their challenge-accepted mentality. We are extremely pleased with global OnPatro and Givlari top-line performance in Q2, which Barry will elaborate on shortly. were also proud of the significant progress we made across our pipeline in the quarter, as Akshay will discuss. Another highlight for the quarter was our landmark strategic financing collaboration and increase around royalty monetization we completed with Blackstone Life Sciences worth up to $2 billion. We believe this collaboration secures our bridge toward a self-sustainable financial profile without the need for any future equity financings. Before I share my closing remarks, I want to take a moment to acknowledge the news we announced earlier this morning about Barry Green's planned departure from El Nile at the end of quarter. Barry and I have been working side-by-side for over 20 years, first at Millennium and then for 17 years at El Nile. And I know that I speak for everyone at El Nile in thanking Barry for his exceptional contributions and dedication to the company. We all owe him tremendous gratitude for his outstanding leadership and track record that have contributed to the delivery of RNAi therapeutics as a whole new class of medicines for patients. I have no doubt Barry will continue to be a highly impactful leader in the life sciences. I'm grateful for his agreement to consult with El Milam as needed for a two-year period, and I wish him all the very best in his next endeavors. We are also very pleased to share that Yvonne Greenstreet, our current chief operating officer, will step into the expanded role of president and chief operating officer on October 1st. We believe Yvonne is uniquely suited for this opportunity, given her strong command of our business, strategic leadership, and proven ability to drive results. We are initiating a search for a chief commercial officer, and during the search, we anticipate no impact to our ongoing commercial execution. Please join me in wishing Barry well as he pursues the next chapter of a remarkable career and congratulating Yvonne on her expanded role at El Milo. I'd like to finish with my perspective on the big picture for the company. Thank you for joining us. Without a doubt, we're excited for the promising future that Alnylam is poised to deliver as a top-tier biopharmaceutical company focused on advancing medicines with transformative potential to patients around the world. With that, I will now turn the call over to Barry for one last time, Barry, to review our commercial progress and medical affairs activities in more detail. Barry, take it away.